NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeOnc Technologies: From Survival Mode To Expansion Mode
NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI's financials are challenging, with no revenue, rising R&D expenses, and a significant cash burn, but a $50M Quazar partnership is set to transform its outlook. The Quazar deal will provide crucial funding, pay off debts, and enable NTHI to accelerate clinical development and expansion in the MENA region.
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.03 per share a year ago.
NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive Officer Warren Stone - President and Chief Operating Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Ali Olivo - Executive Vice President, General Counsel & Business Development Dr. Nate Montgomery - Vice President, Medical Services Conference Call Participants Andrew Brackman - William Blair Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Mike Matson - Needham & Company Matthew Sykes - Goldman Sachs David Westenberg - Piper Sandler Mason Carrico - Stephens Andrew Cooper - Raymond James Mark Massaro - BTIG, LLC Jack Slevin - Jefferies Puneet Souda - SVB Leerink Operator Greetings and welcome to the NeoGenomics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation.
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics: Decent Fundamentals, But Still Overvalued
NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern.
NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgomery - Vice President, Medical Services Conference Call Participants Andrew Brackman - William Blair Puneet Souda - SVB Leerink Jack Slevin - Jefferies Mason Carrico - Stephens Tejas Savant - Morgan Stanley Vivian Bais - BTIG Prashant Kota - Goldman Sachs Dan Brennan - TD Cowen Andrew Cooper - Raymond James Operator Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
